Cancer

Ovarian Cancer Treatment: FDA Approves Clinical Trials for Leads Biolabs’ LBL-033

In a stride towards the development of innovative treatments for cancer, the U.S. Food and Drug Administration (FDA) has granted approval for the Phase I/II clinical trials of LBL-033, an anti-MUC16/CD3 bispecific antibody developed by Leads Biolabs. The biotech company is set to investigate the safety, efficacy, and pharmacokinetics of LBL-033 in combating advanced solid tumors, including ovarian cancer. This bispecific antibody,…

Women’s Health Company Mithra Reports Promising Data for Its CSF-1R Inhibitor in Preclinical Cancer Models

Mithra Pharmaceuticals and BCI Pharma, have announced promising preliminary data from their CSF-1R inhibitor program. The research indicates that Mithra’s lead CSF-1R inhibitor compound displays significant anti-tumor activity, and may work synergistically with PD-1 cancer immune checkpoint inhibitors. The CSF-1R inhibitor demonstrated its efficacy in three preclinical cancer models, modulating the tumor microenvironment and potentially reducing tumor growth by up to 59%.…

Roche’s HPV Screening Test Receives WHO Prequalification

Pharma company Roche has been awarded World Health Organization (WHO) prequalification for its cobas HPV test. This move increases access to critical cervical cancer screening tools in low and lower-middle income countries, where the disease is most prevalent and deadly. Each year, over 600,000 women around the world are diagnosed with cervical cancer, with more than 340,000 succumbing to the preventable disease,…

Novartis’ Kisqali Shows Promising Results in Reducing Breast Cancer Recurrence

Novartis has unveiled significant findings from the Phase III NATALEE trial, demonstrating that Kisqali (ribociclib) can effectively reduce the risk of cancer recurrence by 25.2% in patients with early breast cancer. The trial results were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and showcased a consistent and clinically meaningful benefit of Kisqali across a broad range of…

Women-led Perci Health Adds £3.4M in Seed Funding for Its Digital Cancer Care Platform

Perci Health, an online platform that helps people access multidisciplinary, supportive care throughout their cancer journey, has raised £3.4m in seed funding led by Octopus Ventures. The new funds will allow the company to further invest into its technology roadmap, continue to expand the team and grow access for cancer patients through new partnerships with large employers and insurers. In the last few…

Google Health AI Announces New Women’s Health Partnerships

During its annual health event, The Check Up, Google unveiled several new healthcare partnerships with a focus on artificial intelligence. In recent years, the tech giant has invested significant attention and resources into healthcare in a bid to further integrate itself into the burgeoning industry. One highlight of the event was Google’s announcement that its Med-PaLM 2 language model can now provide…

New Findings from Apple’s Menstrual Health Study Suggest Connection Between PCOS and Endometrial Hyperplasia

Ahead of International Women’s Day, new preliminary findings from the Apple Women’s Health Study underscore the importance of paying attention to the menstrual cycle and its connection to overall health. Many physicians consider periods a vital sign, yet this area of health is notably under-researched. The Apple Women’s Health Study is a first-of-its-kind research study conducted with the Harvard T.H. Chan School of Public…

New Study by MyOme Suggests Cross-Ancestry Polygenic Risk Score Improves Breast Cancer Prediction

MyOme has announced the publication of a validation study for its cross-ancestry, integrated risk score in JCO Precision Oncology. The study tested the association between the caIRS and breast cancer in retrospective data from two validation cohorts with longitudinal follow-up amounting to over 130,000 women and demonstrated that MyOme’s cross-ancestry, integrated risk score significantly improved breast cancer risk prediction over the common…